RSCM
ANTH

Rock Springs Capital Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Rock Springs Capital Management’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-107,630
Closed -$155K – 155
2017
Q3 		$155K Sell
107,630
-58,075
-35% -$82.5K 0.01% 147
2017
Q2 		$268K Buy
165,705
+3,634
+2% +$8.15K 0.01% 149
2017
Q1 		$552K Buy
162,071
+114,571
+241% +$542K 0.03% 138
2016
Q4 		$247K Sell
47,500
-8,750
-16% -$151K 0.02% 133
2016
Q3 		$1.42M Hold
56,250
– – 0.09% 127
2016
Q2 		$1.39M Hold
56,250
– – 0.1% 124
2016
Q1 		$1.63M Buy
56,250
+8,750
+18% +$237K 0.14% 118
2015
Q4 		$1.76M Sell
47,500
-2,500
-5% -$110K 0.13% 111
2015
Q3 		$2.44M Sell
50,000
-8,750
-15% -$611K 0.2% 107
2015
Q2 		$4.05M Buy
58,750
+5,625
+11% +$260K 0.3% 101
2015
Q1 		$1.9M Buy
+53,125
New +$1.57M 0.18% 99

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Rock Springs Capital Management's ANTH Position: Q4 2017 in Review

Rock Springs Capital Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 107,630 shares — an estimated $155K sold.

Rock Springs Capital Management first reported a position in ANTH in Q1 2015 and held it in 11 quarters. The position peaked at $4.05M in Q2 2015. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

  • Rock Springs Capital Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Rock Springs Capital Management sold 107,630 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $155K.
  • Rock Springs Capital Management first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2015 and held it in 11 quarters.
  • Rock Springs Capital Management's Anthera Pharmaceuticals, Inc. position peaked at $4.05M in Q2 2015.
  • 37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Rock Springs Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.